Drug Trial Radar · NCT01107626
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: Jul 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,516
Actual
Start
Oct 25, 2010
Primary completion
Jan 31, 2019
Study completion Aug 17, 2021
Sponsor
- Lead sponsor
- ECOG-ACRIN Cancer Research GroupResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Apr 21, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of non-small cell lung cancer by blocking blood flow to the tumor. Pemetrexed disodium may stop the growth of tumor cells by blocking some enzymes needed for cell growth. It is not yet known whether giving bevacizumab or pemetrexed disodium alone or in combination is more effective in treating non-squamous non-small cell lung cancer. PURPOSE: This randomized phase III trial is studying bevacizumab and pemetrexed disodium alone or in combination after induction therapy to see how well they work in treating patients with advanced non-squamous non-small cell lung cancer.
Conditions
- Lung Cancer
Interventions
PaclitaxelDrug
Given IV
CarboplatinDrug
Given IV
BevacizumabBiological
Given IV
Pemetrexed Disodium HeptahydrateDrug
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall SurvivalTime frame: Assessed every 6 weeks during induction therapy and every 3 cycles during maintenance therapy; after discontinuation of study therapy, assessed every 3 months for 2 years and every 6 months for years 3-5
Locations
434 sites in 1 country. Site status is shown where the registry gives one.
Regional Medical Center
Anniston, Alabama
Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital
Fairbanks, Alaska
North Bay Cancer Center
Fairfield, California
Todd Cancer Institute at Long Beach Memorial Medical Center
Long Beach, California
Community Hospital of the Monterey Peninsula Comprehensive Cancer Center
Monterey, California
Veterans Affairs Medical Center - Palo Alto
Palo Alto, California
Feather River Hospital Cancer Center
Paradise, California
Sutter Cancer Center at Roseville Medical Center
Roseville, California
Sutter Cancer Center
Sacramento, California
Salinas Valley Memorial Hospital
Salinas, California
Stanford Cancer Center
Stanford, California
Aurora Presbyterian Hospital
Aurora, Colorado
Boulder Community Hospital
Boulder, Colorado
Penrose Cancer Center at Penrose Hospital
Colorado Springs, Colorado
St. Anthony Central Hospital
Denver, Colorado
Kaiser Permanente - Denver
Denver, Colorado
Porter Adventist Hospital
Denver, Colorado
Presbyterian - St. Luke's Medical Center
Denver, Colorado
St. Joseph Hospital
Denver, Colorado
Rose Medical Center
Denver, Colorado
CCOP - Colorado Cancer Research Program
Denver, Colorado
Swedish Medical Center
Englewood, Colorado
Poudre Valley Hospital
Fort Collins, Colorado
Front Range Cancer Specialists
Fort Collins, Colorado
North Colorado Medical Center
Greeley, Colorado
Kaiser Permanente - Lafayette
Lafayette, Colorado
Littleton Adventist Hospital
Littleton, Colorado
Sky Ridge Medical Center
Lone Tree, Colorado
Hope Cancer Care Center at Longmont United Hospital
Longmont, Colorado
McKee Medical Center
Loveland, Colorado
Parker Adventist Hospital
Parker, Colorado
St. Mary - Corwin Regional Medical Center
Pueblo, Colorado
North Suburban Medical Center
Thornton, Colorado
Exempla Lutheran Medical Center
Wheat Ridge, Colorado
Praxair Cancer Center at Danbury Hospital
Danbury, Connecticut
Helen and Harry Gray Cancer Center at Hartford Hospital
Hartford, Connecticut
Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
Hartford, Connecticut
George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus
New Britain, Connecticut
Kaiser Permanente at Capitol Hill Medical Center
Washington D.C., District of Columbia
Sibley Memorial Hospital
Washington D.C., District of Columbia
Showing 40 of 434 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.